

Assessment of 2023 ACR/EULAR Antiphospholipid Syndrome classification criteria in a Spanish cohort

Rodrigo Cantera Estefanía, Rafael Gálvez Sánchez, María Abando Casuso, José Antonio Flores García, Raquel García Ruiz, Irene Gorostidi Álvarez, Héctor Cruz Barquín, María Oviedo Madrid, Marina Herrero López, Ligia Gabriela Gabriele Rodríguez, Juan José Domínguez García, Ariadna García Ascacíbar, José Luis Hernández Hernández, Lucrecia Yáñez San Segundo, Belén González-Mesones Galán, María Luisa González Ponte, Marcos López Hoyos, Gala Aglaia Méndez Navarro, Sara del Barrio Longarela, Víctor Manuel Martínez Taboada

Supplementary Table 1. Immune-mediated inflammatory diseases (IMID) in patients that fulfilled the 2006 Sydney and the 2023 ACR/EULAR classification criteria.

		2023 ACR/EULAR Criteria	
		NO N=223	YES N=152
	2006 Sydneycriteria N = 375		
	N (%)	N (%)	N (%)
Psoriatic arthritis	6 (1.6)	5 (2.24)	1 (0.66)
Rheumatoid arthritis	2 (0.53)	2 (0.9)	0
Behcet syndrome + Psoriasis	1 (0.27)	0	1 (0.66)
Ulcerative colitis	2 (0.53)	1 (0.45)	1 (0.66)
UCTD	4 (1.07)	2 (0.9)	2 (1.32)
Celiac disease	1 (0.27)	1 (0.45)	0
Chron's disease	2 (0.53)	1 (0.45)	1 (0.66)
Buerger's disease	1 (0.27)	0	1 (0.66)
Paget's disease	1 (0.27)	1 (0.45)	0
Systemic sclerosis	2 (0.53)	0	2 (1.32)
Axial spondyloarthritis	2 (0.53)	1 (0.45)	1 (0.66)
Autoimmune hypothyroidism	2 (0.53)	1 (0.45)	1 (0.66)
SLE	24 (6.40)	13 (5.83)	11 (7.24)
SLE incomplete	2 (0.53)	1 (0.45)	1 (0.66)
SLE + other	5 (1.33)	3 (1.35)	2 (1.32)
Discoid lupus	1 (0.27)	0	1 (0.66)
Polymyalgia rheumatica	5 (1.33)	5 (2.24)	0
Psoriasis	1 (0.27)	1 (0.45)	0
PIT	1 (0.27)	0	1 (0.66)
Sjogren syndrome	3 (0.8)	1 (0.45)	2 (1.32)

UCTD: Undifferentiated connective tissue disease; SLE: systemic lupus erythematosus; PIT: Primary immune thrombocytopenia.